GNTA
Genenta Science S.p.A. [GNTA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
GNTA Stock Summary
Top 10 Correlated Stocks
GNTA
In the News
GNTA Financial details
Company Rating
-
Market Cap
63.14M
Income
-11.49M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
14
Optionable
No
Shortable
Yes
Earnings
28 Aug 2024
P/E
-20.88
Forward P/E
-
PEG
-0.53
P/S
-
P/B
2.43
P/C
-
P/FCF
-10.17
Quick Ratio
14.36
Current Ratio
14.53
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.99
EPS next Y
-
EPS next Q
-
EPS this Y
215%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-29.73%
-
-
-
-
SMA20
-4.72%
SMA50
2.02%
SMA100
-4.72%
Inst Own
-
Inst Trans
-
ROA
-11%
ROE
-10%
ROC
-0.35%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.11-6.81
52W High
-38.5%
52W Low
+23%
RSI
34.06
Rel Volume
0.19
Avg Volume
4.56K
Volume
853
Perf Week
-15.37%
Perf Month
-7.05%
Perf Quarter
-28.35%
Perf Half Y
-28.76%
-
-
-
-
Beta
0.716
-
-
Volatility
0.18%, 0.2%
Prev Close
-4.9%
Price
3.69
Change
-2.38%
Company Profile
- Volume Average 4.56K
- Market Capitalization 63.14M
- Employee 14
- CEO Mr. Pierluigi Paracchi
- Headquarters Milan,MI,IT
- IPO Date 2021-12-15
-
Website
https://www.genenta.com 
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.
